BMGL (Basel Medical Group) EBIT: $-7.86 Mil (TTM As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BMGL Basel Medical Group Ltd BMGL
17 GF Score
Price $5.70
! 3 Warning Signs
View Full Analysis

What is Basel Medical Group EBIT?

Basel Medical Group BMGL -7.17% 17 EBIT is $-7.86 Mil as of Dec. 2025. GuruFocus rates BMGL with a GF Score™ of 17/100. The stock has 3 warning signs investors should review.

Basel Medical Group's earnings before interest and taxes (EBIT) for the six months ended in Dec. 2025 was $0.43 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Dec. 2025 was $-7.86 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Basel Medical Group's annualized ROC % for the quarter that ended in Dec. 2025 was -25.25%. Basel Medical Group's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2025 was 11.35%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Basel Medical Group's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2025 was -52.35%.

Basel Medical Group  (NAS:BMGL) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Basel Medical Group's annualized ROC % for the quarter that ended in Dec. 2025 is calculated as:

ROC % (Q: Dec. 2025 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Jun. 2025 ) + Invested Capital (Q: Dec. 2025 ))/ count )
=-4.488 * ( 1 - 52.31% )/( (5.935 + 11.016)/ 2 )
=-2.1403272/8.4755
=-25.25 %

where

Invested Capital(Q: Jun. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=14.565 - 6.257 - ( 2.373 - max(0, 7.923 - 10.366+2.373))
=5.935

Invested Capital(Q: Dec. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=15.592 - 3.535 - ( 1.041 - max(0, 5.828 - 10.984+1.041))
=11.016

Note: The Operating Income data used here is two times the semi-annual (Dec. 2025) data.

2. Joel Greenblatt's definition of Return on Capital:

Basel Medical Group's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2025 is calculated as:

ROC (Joel Greenblatt) %(Q: Dec. 2025 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Jun. 2025  Q: Dec. 2025
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=0.856/( ( (4.162 + max(1.433, 0)) + (4.571 + max(4.912, 0)) )/ 2 )
=0.856/( ( 5.595 + 9.483 )/ 2 )
=0.856/7.539
=11.35 %

where Working Capital is:

Working Capital(Q: Jun. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(1.678 + 0.381 + 5.643) - (6.257 + 0 + 0.012)
=1.433

Working Capital(Q: Dec. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(2.505 + 0.258 + 5.696) - (3.535 + 0 + 0.012)
=4.912

When net working capital is negative, 0 is used.

Note: The EBIT data used here is two times the semi-annual (Dec. 2025) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Basel Medical Group's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Dec. 2025 )
=-7.861/15.015
=-52.35 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Basel Medical Group EBIT Related Terms

Basel Medical Group EBIT Historical Data

* Premium members only.

The historical data trend for Basel Medical Group's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Basel Medical Group EBIT Chart

Basel Medical Group Annual Data
Trend Jun22 Jun23 Jun24 Jun25
EBIT
1.96 1.76 1.91 -8.46

Basel Medical Group Semi-Annual Data
Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
EBIT Get a 7-Day Free Trial 1.53 0.41 -0.16 -8.29 0.43

BMGL vs AMS, HLYK, BICX: EBIT Comparison

For the Medical Care Facilities subindustry, Basel Medical Group's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Basel Medical Group EV-to-EBIT vs Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, Basel Medical Group's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Basel Medical Group's EV-to-EBIT falls into.


BMGL
17GF Score
Basel Medical Group Ltd BMGL
EBIT is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Basel Medical Group EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was $-7.86 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT →
What does a EBIT of $-7.86 Mil mean?
Basel Medical Group (BMGL) has a EBIT of $-7.86 Mil as of Dec. 2025. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Basel Medical Group.
Is Basel Medical Group's EBIT too high?
Basel Medical Group's current EBIT is $-7.86 Mil. Overall, Basel Medical Group has a GF Score™ of 17/100, reflecting its overall financial health beyond just this single metric.
How does Basel Medical Group's EBIT compare to AMS and HLYK?
Basel Medical Group's EBIT of $-7.86 Mil can be compared against companies in the Healthcare Providers & Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Healthcare Providers & Services company?
A good EBIT depends on the Healthcare Providers & Services industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Basel Medical Group. Basel Medical Group's current EBIT is $-7.86 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Basel Medical Group stock overvalued right now?
Basel Medical Group (BMGL) has a current EBIT of $-7.86 Mil. The current EBIT is $-7.86 Mil. Basel Medical Group's overall GF Score™ is 17/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For Basel Medical Group (BMGL), the current EBIT is $-7.86 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Basel Medical Group Business Description

Address 6 Napier Road, Unit No. 02-10/11, Gleneagles Medical Centre, Singapore, SGP, 258499
Basel Medical Group Ltd provides general and subspecialized orthopedic, trauma and sports medicine services such as knee/hip replacements, sports medicine/surgery, spine surgery, foot/ankle surgery and minimally invasive orthopedic procedures, as well as neurosurgical treatments. The services provided by clinics include, but are not limited to, consultation, medical diagnosis and medical or surgical treatments for orthopedic, trauma, sports medicine, general practice, health screening, mental health, women's health and neurosurgical conditions and clinics are equipped with the facilities needed to perform a variety of procedures on site and minor surgical services. Key revenue is generated from Singapore.
17GF Score

Get the complete analysis for BMGL

EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$5.70
Price